Ian C. Lennon was born in Lisburn, N. Ireland in 1963. He graduated from the University of St. Andrews in 1985 with a BSc in Chemistry then worked for Merck, Sharp & Dohme Harlow, Essex, in drug discovery. In 1989 he left Merck to study for a PhD with Steve Ley at Imperial College, London. In 1993 Ian joined Chiroscience and in 1995 he carried out a secondment with Barry Trost at Stanford University to evaluate his palladium(0) catalysed asymmetric allylic alkylation technology. Ian was Head of Collaborative Research for Chirotech, between 1997 and 2001, and managed over 100 projects for fine chemical and pharmaceutical companies in the area of chiral chemistry. In 2000 Ian’s responsibilities were extended to include management of the chemocatalysis core research team. Chirotech was acquired by The Dow Chemical Company in 2001 and Ian became Scientist and Technology leader for Chemocatalysis in Dowpharma. The UK assets of Dowpharma were acquired by Dr Reddy’s in May 2008 and Ian joined Chiral Quest in January 2009 as Senior Vice President, Global Business Development. Ian is responsible for business development and the promotion of Chiral Quest’s technology portfolio worldwide. Ian is an Editorial Advisory Board member of Organic Process Research & Development and Chimica Oggi. He is an author/co-author of over 66 technical publications and 6 patents.